What is it about?
Levofloxacin is a fluoroquinolone that has a broad spectrum of activity against several causative bacterial pathogens of community-acquired pneumonia (CAP). The efficacy and tolerability of levofloxacin 500 mg once daily for 10 days in patients with CAP are well established. Furthermore, a high-dose (750 mg), short-course (5 days) of once-daily levofloxacin has been approved for use in the USA in the treatment of CAP, acute bacterial sinusitis, acute pyelonephritis and complicated urinary tract infections. Levofloxacin can be used as a monotherapy in patients with CAP, however, levofloxacin combination therapy with anti-pseudomonal beta-lactam (or aminoglycoside) should be considered if Pseudomonas aeruginosa is the causative pathogen of the respiratory infection. The high-dose, short-course levofloxacin regimen maximizes its concentration-dependent antibacterial activity, decreases the potential for drug resistance and has better patient compliance.
Featured Image
Why is it important?
It is important to carry levofloxacin directly to the lung using lung surfactant in order to decrease the dose and side effects.
Perspectives
Levofloxacin-loaded liposomes exhibited suitable properties for the pulmonary treatment of P. aeruginosa and many other bacteria.
Dr Andre S Pimentel
Pontificia Universidade Catolica do Rio de Janeiro
Read the Original
This page is a summary of: Interaction of levofloxacin with lung surfactant at the air-water interface, Colloids and Surfaces B Biointerfaces, October 2017, Elsevier,
DOI: 10.1016/j.colsurfb.2017.07.066.
You can read the full text:
Contributors
The following have contributed to this page
